Insulin Resistance Is Associated With Reduced Capillary Permeability of Thigh Muscles in Patients With Type 2 Diabetes

CONTEXT

Insulin-mediated microvascular permeability and blood flow of skeletal muscle appears to be altered in the condition of insulin resistance. Previous studies on this effect used invasive procedures in humans or animals.

OBJECTIVE

The aim of this study was to demonstrate the feasibility of a noninvasive assessment of human muscle microcirculation via dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) of skeletal muscle in patients with type 2 diabetes (T2D).

METHODS

A total of 56 participants (46 with T2D, 10 healthy controls [HC]) underwent DCE-MRI of the right thigh at 3 Tesla. The constant of the musculature's microvascular permeability (Ktrans), extravascular extracellular volume fraction (ve), and plasma volume fraction (vp) were calculated.

RESULTS

In T2D patients, skeletal muscle Ktrans was lower (HC 0.0677 ± 0.002 min-1, T2D 0.0664 ± 0.002 min-1; P = 0.042) while the homeostasis model assessment (HOMA) index was higher in patients with T2D compared to HC (HC 2.72 ± 2.2, T2D 6.11 ± 6.2; P = .011). In T2D, Ktrans correlated negatively with insulin (r = -0.39, P = .018) and HOMA index (r = -0.38, P = .020).

CONCLUSION

The results signify that skeletal muscle DCE-MRI can be employed as a noninvasive technique for the assessment of muscle microcirculation in T2D. Our findings suggest that microvascular permeability of skeletal muscle is lowered in patients with T2D and that a decrease in microvascular permeability is associated with insulin resistance. These results are of interest with regard to the impact of muscle perfusion on diabetic complications such as diabetic sarcopenia.

[An overview of immune checkpoint inhibitors toxicities]

The development of immune checkpoint inhibitors has led to many breakthroughs in cancer treatment. As their use in many types of cancer expands, oncologists have seen the emergence of a whole new set of adverse events that require specific treatment and attention as they can lead to treatment discontinuation, hospitalization, and death. The molecular pathways targeted by these new pharmaceutical agents aim to remove the inhibition on the anti-tumoral immune response exerted by cancer cells. However, in doing so, they also impact mechanisms important for self-tolerance, and lead to autoimmune-related reactions. Those adverse events can affect every organ, with various frequencies, sometimes a long time after the end of treatment. The following presentation endeavours to list the reported immune adverse events classified by affected organs and gives an overview of the proposed treatment and patient care.